Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology, today announced that it has signed a framework agreement for an exclusive licence with Genostics Company Limited a Hong Kong registered company part of the Gene Group Holdings Limited group, a leading R&D, manufacturing, marketing and distribution Company in China focused on immunological and molecular diagnostic products in the fields of oncology, pathology, hematology and cytogenetics. The agreement is for the distribution, manufacturing and future development of all products related to Oncimmune’s EarlyCDT(R) platform for the People’s Republic of China, with an initial focus on EarlyCDT(R)-Lung. Cancer is the leading cause of death in China and a major health problem and lung cancer is the number one killer of both men and women with over 700,000 cases diagnosed annually. Early diagnosis has the potential to make a significant impact as mortality increases sharply with advanced disease.
Geoffrey Hamilton-Fairley, CEO of Oncimmune, commented: “Oncimmune continues to deliver on our stated strategy at the time of the IPO; a key part of this was a commercial agreement for China. “Today, we are delighted to have signed an agreement for the EarlyCDT(R) platform with Genostics for the People’s Republic of China, a partner we have confidence has the reach to deliver on this very large market opportunity. We look forward to working with them and believe the funds from the equity subscription of this deal will unlock further opportunities across indications as well allowing us to develop new technologies that will result in more lives being saved, at the same time as money is saved for healthcare systems.”
The framework sets the terms for the licence agreement under which Genostics will start to sell EarlyCDT(R)-Lung within 36 months of the date of the agreement, subject to China FDA (“CFDA”) approval, although both parties expect this to be sooner. Oncimmune will receive a royalty of c.8% on the gross revenue subject to minimum royalty payments over the first six years post market entry of GBP15.7 million on aggregate and GBP5 million (index linked) per year thereafter.
As part of the framework agreement, Genostics has agreed, subject to Shareholder approval, to invest GBP10m in Oncimmune by way of subscription for 6,410,256 new ordinary shares at a price of GBP1.56 per ordinary share, a 49% premium to the share price of 105p at market close on 29 December 2017 (“Genostics Subscription”). This will be allocated in two tranches, the first GBP7m following a General Meeting expected to be held later in January 2018, and the second (GBP3m) by 30 March 2018. The exclusive technology licence agreement will be signed following the first subscription. Application will be made for the New Ordinary Shares to be admitted to trading on AIM (“Admission”).
It has also been agreed that a representative from Genostics will be appointed to the Board of Directors of Oncimmune. An announcement will be made once this is finalised.
As part of the agreement with Genostics, GeneTech(Shanghai), a subsidiary of GGH, will be responsible for the manufacturing, marketing and distribution of EarlyCDT(R)-Lung. In addition to this and in collaboration with Oncimmune, a potential to transfer of manufacturing to China for that market and the rest of the world will be explored, as well as research and development to progress the Oncimmune EarlyCDT(R) platform technology into new areas of prevalent cancers.
Dr. Cheung To, Chairman, Genostics Co. Limited, “Genostics is delighted to sign this agreement with Oncimmune and we are excited by the prospect of commercialising the EarlyCDT(R)platform in the People’s Republic of China. The test has proven it can detect cancer up to four years earlier than other methods and this has the potential to significantly improve the outcomes for cancer patients through early detection of the disease and by enhancing the treatment pathway.
“This deal means we can now offer early detection of cancer which augments our product portfolio in our specialized area of pathology and oncology. The EarlyCDT(R) platform is complementary to our current molecular diagnostic product line which uses the latest PCR, sequencing and microarray technologies and, by combining forces with Oncimmune, we will accelerate the technological and commercial development of the EarlyCDT(R) platform, which will ultimately benefit more Chinese patients.”
